

Medtronic launches cryoballoon catheter for treatment of atrial fibrillation in India

09 November 2021 | News

First patient in India treated at Max Hospital, Saket

India Medtronic has announced the launch of Arctic Front™ Cardiac Cryoablation Catheter System, the first and only cryoballoon catheter approved by the Central Drugs Standard Control Organisation (CDSCO) for treatment of atrial fibrillation (AF) in India.

Dr. Balbir Singh, chairman of Cardiology, Pan Max Hospital Saket, Delhi, successfully performed the first procedure in India using the Arctic Front Cardiac Cryoablation Catheter System. Cryoballoon catheter ablation, a minimally invasive procedure, is one of the therapeutic modalities to manage AF.

“AF is a progressive disease, meaning over time patients can experience more frequent, and longer episodes. Cryoballoon ablation is a safe and effective treatment before or after medication therapy to control atrial fibrillation,” said Dr. Singh. “By treating patients with the most advanced, clinically relevant technology, we are better equipped to successfully manage their atrial fibrillation, thereby improving their overall quality-of-life.”

The Medtronic cryoballoon catheter was developed specifically to achieve pulmonary vein isolation. This innovative technique has been used to treat more than 1,000,000 patients in more than 80 countries with robust safety and effectiveness evidence in more than 1200 peer-reviewed articles.